Atul Verma

Atul Verma

Auto-generated profile, based on publicly available information

Atul Verma

McGill University Health Center, Montréal, Canada (A.V.).

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2015 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
AVAtul Verma
Atul Verma
CJChen-Yang Jiang
Chen-Yang Jiang
TBTimothy Betts
Timothy Betts
JCJian Chen
Jian Chen
IDIsabel Deisenhofer
Isabel Deisenhofer
PSPrashanthan Sanders
Prashanthan Sanders
Catheter ablation is less successful for persistent atrial fibrillation than for paroxysmal atrial fibrillation. Guidelines suggest that adjuvant substrate modification in addition to pulmonary-vein isolation is required in persistent atrial fibrillation.

30 March 2024 in EP Europace
Verified
Journal Article
Open access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P Gerstenfeld
Edward P Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo B Saad
Eduardo B Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
STSerge A Trines
Serge A Trines
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society .

9 May 2023 in Circulation
Verified
Journal Article
Open access
AVAtul Verma
Atul Verma
DHDavid E. Haines
David E. Haines
LBLucas V. Boersma
Lucas V. Boersma
NSNitesh Sood
Nitesh Sood
ANAndrea Natale
Andrea Natale
DDDavid B. DeLurgio
David B. DeLurgio
Background: Pulsed field ablation uses electrical pulses to cause nonthermal irreversible electroporation and induce cardiac cell death. Pulsed field ablation may have effectiveness comparable to traditional catheter ablation while preventing thermally mediated complications. Methods: The PULSED AF pivotal study (Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF) was a prospective, global, multicenter, nonrandomized, paired single-arm study in which patients with paroxysmal (n=150) or persistent (n=150) symptomatic atrial fibrillation (AF) refractory to class I or III antiarrhythmic drugs were treated with pulsed field ablation. All patients were monitored for 1 year using weekly and symptomatic transtelephonic monitoring; 3-, 6-, and 12-month ECGs; and 6- and 12-month 24-hour Holter monitoring. The primary effectiveness end point was freedom from a composite of acute procedural failure, arrhythmia recurrence, or antiarrhythmic escalation through 12 months, excluding a 3-month blanking period to allow recovery from the procedure. The primary safety end point was freedom from a composite of serious procedure- and device-related adverse events. Kaplan-Meier methods were used to evaluate the primary end points. Results: Pulsed field ablation was shown to be effective at 1 year in 66.2% (95% CI, 57.9 to 73.2) of patients with paroxysmal AF and 55.1% (95% CI, 46.7 to 62.7) of patients with persistent AF. The primary safety end point occurred in 1 patient (0.7%; 95% CI, 0.1 to 4.6) in both the paroxysmal and persistent AF cohorts. Conclusions: PULSED AF demonstrated a low rate of primary safety adverse events (0.7%) and provided effectiveness consistent with established ablation technologies using a novel irreversible electroporation energy to treat patients with AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04198701.

26 November 2019 in Circulation
Verified
Journal Article
Closed access
PDF file
JAJason G Andrade
Jason G Andrade
JCJean Champagne
Jean Champagne
MDMarc Dubuc
Marc Dubuc
MDMarc W. Deyell
Marc W. Deyell
AVAtul Verma
Atul Verma
LGLorne Gula
Lorne Gula
Background: Advanced generation ablation technologies have been developed to achieve more effective pulmonary vein isolation (PVI) and minimize arrhythmia recurrence after atrial fibrillation (AF) ablation. Methods: We randomly assigned 346 patients with drug-refractory paroxysmal AF to contact force–guided radiofrequency ablation (CF-RF; n=115), 4-minute cryoballoon ablation (Cryo-4; n=115), or 2-minute cryoballoon ablation (Cryo-2; n=116). Follow-up was 12 months. The primary outcome was time to first documented recurrence of symptomatic or asymptomatic atrial tachyarrhythmia (AF, atrial flutter, or atrial tachycardia) between days 91 and 365 after ablation or a repeat ablation procedure at any time. Secondary end points included freedom from symptomatic arrhythmia and AF burden. All patients received an implantable loop recorder. Results: One-year freedom from atrial tachyarrhythmia defined by continuous rhythm monitoring was 53.9%, 52.2%, and 51.7% with CF-RF, Cryo-4, and Cryo-2, respectively ( P =0.87). One-year freedom from symptomatic atrial tachyarrhythmia defined by continuous rhythm monitoring was 79.1%, 78.2%, and 73.3% with CF-RF, Cryo-4, and Cryo-2, respectively ( P =0.26). Compared with the monitoring period before ablation, AF burden was reduced by a median of 99.3% (interquartile range, 67.8%–100.0%) with CF-RF, 99.9% (interquartile range, 65.3%–100.0%) with Cryo-4, and 98.4% (interquartile range, 56.2%–100.0%) with Cryo-2 ( P =0.36). Serious adverse events occurred in 3 patients (2.6%) in the CF-RF group, 6 patients (5.3%) in the Cryo-4 group, and 7 patients (6.0%) in the Cryo-2 group, with no significant difference between groups ( P =0.24). The CF-RF group had a significantly longer procedure duration but significantly shorter fluoroscopy exposure ( P 98% burden reduction as assessed by continuous cardiac rhythm monitoring. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01913522.

8 April 2024 in Heart Rhythm
Verified
Journal Article
Open access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo B. Saad
Eduardo B. Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
EWElaine Y. Wan
Elaine Y. Wan
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society.

1 October 2014 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
AVAtul Verma
Atul Verma
JCJohn A. Cairns
John A. Cairns
LML. Brent Mitchell
L. Brent Mitchell
LMLaurent Macle
Laurent Macle
ISIan G. Stiell
Ian G. Stiell
JHJeff S. Healey
Jeff S. Healey